Emerging PEGylated drugs (Q33447691)

26 July 2017

1 reference

title

Emerging PEGylated drugs (English)

1 reference

26 July 2017

Jung Seok Kang

1

1 reference

26 July 2017

Patrick P Deluca

series ordinal

2

1 reference

26 July 2017

Kang Choon Lee

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Emerging Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

14

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

363-380

1 reference

Pharmacokinetic consequences of pegylation

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

PEGylation, successful approach to drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Effect of pegylation on pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Process economics of industrial monoclonal antibody manufacture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

PEGylated antibodies and antibody fragments for improved therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Certolizumab pegol: in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Anti-cancer PEG-enzymes: 30 years old, but still a current approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pegaspargase: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

The impact of PEGylation on biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pegvisomant in the treatment of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

CERA: third-generation erythropoiesis-stimulating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Enzymatic procedure for site-specific pegylation of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Peptide and protein PEGylation: a review of problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Releasable PEGylation of proteins with customized linkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Effective drug delivery by PEGylated drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pegylated arginine deiminase: a novel anticancer enzyme agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

A SHORT METHOD FOR THE PURIFICATION OF ARGINASE FROM OX LIVER

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Clinical development of PEGylated recombinant staphylokinase (PEG–Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

PEGylation of growth hormone-releasing hormone (GRF) analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Development and in vivo evaluation of an oral insulin-PEG delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Monoclonal antibody "gold rush".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Therapeutic antibody fragments with prolonged in vivo half-lives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902907847

10.1517/14728210902907847

21 January 2018

Identifiers

DOI

1 reference

release_hbh7ob65drdinbucrgz2vz6fe4

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hbh7ob65drdinbucrgz2vz6fe4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference